Emily E. Van Seventer

Also affiliated with University of California, San Francisco, Massachusetts General Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors”.

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3135

N/A

0.546DataRank · unranked

37 citations

T. Khanh, Jeong Eun Kim, James M. Cleary, Aparna R. Parikh, Oladapo Yeku +26 more

Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3660

N/A

0DataRank · unranked

16 citations

Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia Patel +13 more